A Phase 1a Study of CUSP06 in People With Ovarian or Endometrial Cancer

Full Title

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-directed Antibody-Drug Conjugate, in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Purpose

Researchers are finding the best dose of CUSP06 to use in people with advanced ovarian or endometrial cancer. The people in this study have cancer that came back or keeps growing after treatment.

CUSP06 targets cells that have CDH6, a protein which plays a role in cancer cell growth. By destroying these cells, CUSP06 may help slow or stop the growth of your cancer. CUSP06 is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Roisin O’Cearbhaill’s office at 646-608-2091.